Acquisition Announced
Tempus AI acquisition of Personalis
US$1.9bn equity value
Announced 20 Jul 2026 · NASDAQ: PSNL · US$16.25 cash and scrip per share
Advisers
Personalis
Target
- Financial adviser
- Legal adviser
- Target
- Personalis
- Acquirer
- Tempus AI
- Target based in
- United States
- Buyer based in
- United States
- Sector
- Diagnostics
- Tags
- Diagnostics, Oncology, Life Sciences
In the league tables
Similar deals
- Proposed Ignite Proteomics Inc. holding company and Ignite Proteomics merger Jun 2026 · US$150m · Life Sciences
- Astorg acquisition of Thermo Fisher Scientific's microbiology division Apr 2026 · US$1.1bn · Diagnostics
- Agilent Technologies acquisition of Biocare Medical Mar 2026 · US$950m · Diagnostics
- Perceptive Capital Solutions Corp and Freenome Holdings merger Dec 2025 · US$725m · Diagnostics
- Roche acquisition of SAGA Diagnostics Jun 2026 · US$595m · Diagnostics
Sources
- 2026 Centerview Partners: Centerview as lead advisor to Personalis on their sale to Tempus AI centerviewpartners.com
- Jul 2026 Latham Advises Tempus AI on Acquisition of Personalis lw.com
- 20 Jul 2026 Personalis to be Acquired by Tempus AI for $1.9 Billion cooley.com
- 31 Aug 2026 Going-private transaction statement (SC 13E3), Personalis, Inc. sec.gov


